Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.34 +0.05 (+0.19%)
Streaming Delayed Price Updated: 2:37 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety... 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.